UBS lowered the firm’s price target on Aflac (AFL) to $114 from $116 and keeps a Neutral rating on the shares. The firm adjusted targets in the North American life insurance group as part of a Q1 earnings preview. UBS expects continued focus on disability margins with “relatively limited wiggle-room” given cyclicality and economic uncertainty. The firm rolled its target to 2027 from 2026 estimates.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on AFL:
- ImmunityBio, Keysight, Rubrik, AFLAC, Moody’s Insider Shake-Up
- Insiders Rock Asana, Ibio, Redwire, AFLAC, Sibanye Stillwater
- Aflac re-initiated with a Market Perform at Keefe Bruyette
- Aflac price target raised to $118 from $109 at Wells Fargo
- The Week That Was, The Week Ahead: Macro and Markets, Feb. 15